Akebia Therapeutics (AKBA) Stock Price, Quote & News

Company Profile

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients; and Auryxia, a ferric citrate that is used to control the serum phospho...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 617 871 2098

Fax: 617 871 2099

Website: www.akebia.com

Address:

245 First Street, Suite 1400, Cambridge, United States

TheUltimatePayoff Sep. 17 at 6:43 AM

$AKBA $3.20

0 · Reply

Quinnlucky Sep. 17 at 6:42 AM

$AKBA UK's GSK announces $30 billion U.S. pharma investment amid Trump state visit https://www.cnbc.com/2025/09/17/uks-gsk-announces-30-billion-us-pharma-investment-amid-trump-state-visit.html?__source=iosappshare%7Ccom.apple.UIKit.activity.CopyToPasteboard

0 · Reply

Mr_Pithy Sep. 17 at 6:37 AM

$AKBA Hornz continues to hold 2,500,000+ shares. Hornz loves ❤️ the long and strong. Hornz is betting on USRC, DCI, IRC, Davita, etc. Hornz is relying on new SOC. Hornz is counting on $12B to $13B asset evaluation. Hornz is trusting on “manageable, quick, successful” Vafseo NDD trial. Hornz is hoping on $30.00 price projection by @hsainu June 30, 2026. Hornz hates the Tutes who manipulate and suppress price to shake out weak hands. Hornz hates the flippers and shorts who scavenge off AKBA. Hornz hates most the lying, lowlife, scumbag FatTummy, Greedy, Vinny, etc. To almost everyone else, Hornz wishes the very best of luck. 🍀

1 · Reply

Noname2022 Sep. 17 at 3:55 AM

$AKBA

0 · Reply

PharmaExpert Sep. 17 at 2:48 AM

$AKBA Major Surge is Imminent! 🔥

1 · Reply

georgeyann Sep. 17 at 2:19 AM

$AKBA strong buy!

1 · Reply

buckeye1979 Sep. 17 at 1:29 AM

$AKBA I have seen a lot of dumb posts on here, but this is definitely a contender for the “here is your sign” award. Pumpers sold and promoting the stock…explain the financial benefit in that?

3 · Reply

GOLA_K Sep. 17 at 1:23 AM

$AKBA SELL, SELL, Before CRL, AKBA and now same price, What Vasio impact?? JB, Why boards are not firing you.

1 · Reply

IVAlert Sep. 17 at 1:02 AM

$AKBA 30-Day Options IV is 84.4%% 60-Day Options IV is 66.9%% Options are currently 17.5% more expensive than the historical IV (60-day). It's a good time to be selling premiums as the options premiums are overvalued $AKBA Options Trading Guidance: Sell options premium https://ivalerts.com/trades

0 · Reply

King_JK Sep. 17 at 12:52 AM

$AKBA What did I say earlier...? Watch the CEOs and boards of directors at TSLA and OPEN! That's what truly matters to shareholders, not just rewarding the CEO with stock all the time! $TSLA $OPEN

0 · Reply

Akebia Therapeutics, Inc. (AKBA) Presents at Wells Fargo 20th Annual Healthcare Conference 2025 Transcript

Sep 2, 2025, 4:05 PM EDT - 14 days ago

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Aug 28, 2025, 8:17 AM EDT - 19 days ago

Akebia Therapeutics: Post-Earnings Dip Looks Like A Discounted Entry Ahead Of A Vafseo Inflection

Aug 28, 2025, 8:00 AM EDT - 19 days ago

Akebia Therapeutics to Present at Upcoming Investor Conferences

Aug 21, 2025, 8:00 AM EDT - 26 days ago

Akebia Therapeutics and Innovative Renal Care Announce Nationwide Availability of Vafseo® (vadadustat) Across All IRC Dialysis Clinics

Aug 7, 2025, 7:34 PM EDT - 5 weeks ago

Akebia Therapeutics, Inc. (AKBA) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 7:00 AM EDT - 5 weeks ago

Akebia Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights

Aug 6, 2025, 8:00 AM EDT - 5 weeks ago

Akebia Therapeutics to Present at Canaccord Genuity's 45th Annual Growth Conference

Aug 4, 2025, 8:00 AM EDT - 6 weeks ago

Akebia Initiates Vafseo® (vadadustat) Post-Marketing Study in Conjunction with Large Dialysis Organization

Aug 1, 2025, 4:05 PM EDT - 6 weeks ago

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jul 31, 2025, 8:00 AM EDT - 6 weeks ago

Akebia Therapeutics to Report Second Quarter 2025 Financial Results and Discuss Recent Business Highlights

Jul 8, 2025, 8:00 AM EDT - 2 months ago

Akebia Therapeutics to Present at the H.C. Wainwright 4th Annual Kidney Virtual Conference

Jun 4, 2025, 8:00 AM EDT - 3 months ago

Vadadustat U.S. Patient Data from Global Phase 3 Clinical Program Published in Journal of the American Society of Nephrology

May 28, 2025, 8:00 AM EDT - 3 months ago

Akebia Therapeutics to Present at the Jefferies Global Healthcare Conference 2025

May 27, 2025, 8:00 AM EDT - 4 months ago

Akebia Therapeutics Announces Three Poster Presentations at the European Renal Association Congress 2025

May 13, 2025, 8:00 AM EDT - 4 months ago

Akebia Therapeutics to Present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference

May 8, 2025, 12:44 PM EDT - 4 months ago

Akebia Therapeutics, Inc. (AKBA) Q1 2025 Earnings Call Transcript

May 8, 2025, 7:00 AM EDT - 4 months ago

Akebia Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights

May 1, 2025, 8:00 AM EDT - 4 months ago

Akebia Therapeutics to Report First Quarter 2025 Financial Results and Discuss Recent Business Highlights

Apr 3, 2025, 8:00 AM EDT - 5 months ago

Akebia Therapeutics Announces Positive Opinion of European Medicines Agency for XOANACYL®, an Oral Therapy for Chronic Kidney Disease Licensed to Averoa

Mar 25, 2025, 8:00 AM EDT - 6 months ago

Akebia Therapeutics Announces Poster Presentations at NKF Spring Clinical Meetings 2025

Mar 20, 2025, 8:18 AM EDT - 6 months ago

JOYY, Akebia Therapeutics, Microchip Technology And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

MCHP

Mar 19, 2025, 10:17 PM EDT - 6 months ago

Akebia Therapeutics Announces Pricing of Public Offering of Common Stock

Mar 19, 2025, 4:01 PM EDT - 6 months ago

Akebia Therapeutics Announces Proposed Public Offering of Common Stock

Mar 13, 2025, 10:21 AM EDT - 6 months ago

Akebia Therapeutics, Inc. (AKBA) Q4 2024 Earnings Call Transcript

Mar 13, 2025, 7:00 AM EDT - 6 months ago

Akebia Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Vafseo® (vadadustat) Commercial Launch Progress Update

Mar 6, 2025, 8:00 AM EST - 6 months ago

Akebia Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Discuss Recent Business Highlights

Feb 10, 2025, 5:43 AM EST - 7 months ago

Akebia Therapeutics: Still Bullish On Vafseo As Auryxia's Revenues Decline

Jan 13, 2025, 8:00 AM EST - 8 months ago

Akebia Therapeutics Announces Multiple Positive Business Updates

Dec 18, 2024, 8:00 AM EST - 9 months ago

Akebia Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 3, 2024, 7:00 AM EST - 10 months ago

U.S. Renal Care Enrolled First Patients in the VOICE Collaborative Clinical Trial of Vafseo® (vadadustat) for CKD Patients on Dialysis

Nov 25, 2024, 8:00 AM EST - 10 months ago

Akebia Therapeutics to Present at the 36th Annual Piper Sandler Healthcare Conference

Nov 20, 2024, 3:31 PM EST - 10 months ago

Q3 2024 Earnings: Hold Akebia Therapeutics

Nov 14, 2024, 8:00 AM EST - 10 months ago

Vadadustat Alternative Dosing Study Results Published in the American Journal of Kidney Disease

Nov 12, 2024, 8:00 AM EST - 11 months ago

Akebia Therapeutics to Present at the Jefferies London Healthcare Conference

Nov 7, 2024, 1:59 PM EST - 11 months ago

Akebia Therapeutics, Inc. (AKBA) Q3 2024 Earnings Call Transcript

Nov 7, 2024, 7:00 AM EST - 11 months ago

Akebia Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Nov 1, 2024, 8:00 AM EDT - 11 months ago

Akebia Therapeutics to Report Third Quarter 2024 Financial Results and Discuss Recent Business Highlights

Oct 22, 2024, 8:00 AM EDT - 11 months ago

Akebia Therapeutics Signs Commercial Supply Contract with Leading Dialysis Organization to Enable Access to Vafseo® (vadadustat) for Patients on Dialysis

Oct 15, 2024, 8:00 AM EDT - 1 year ago

Akebia Therapeutics Announces Seven Poster Presentations at ASN Kidney Week 2024

Oct 10, 2024, 8:00 AM EDT - 1 year ago

CMS Grants TDAPA Reimbursement for Vafseo® (vadadustat) beginning January 1, 2025

Oct 7, 2024, 8:00 AM EDT - 1 year ago

Akebia Therapeutics and U.S. Renal Care Sign Commercial Supply Contract to Enable Access to Vafseo® (vadadustat) for Patients on Dialysis

Sep 5, 2024, 8:00 AM EDT - 1 year ago

Akebia Therapeutics and U.S. Renal Care Initiate the VOICE Trial of Vafseo® (vadadustat) for Patients on Dialysis

Aug 10, 2024, 1:00 AM EDT - 1 year ago

Akebia Therapeutics, Inc. (AKBA) Q2 2024 Earnings Call Transcript

Aug 8, 2024, 7:00 AM EDT - 1 year ago

Akebia Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

Aug 2, 2024, 8:00 AM EDT - 1 year ago

Akebia Therapeutics to Report Second Quarter 2024 Financial Results and Discuss Recent Business Highlights

Jul 11, 2024, 6:00 AM EDT - 1 year ago

Akebia Therapeutics Provides Update on Continued Momentum of Commercial Launch of Vafseo® (vadadustat) Tablets

Jun 27, 2024, 8:18 AM EDT - 1 year ago

Akebia Therapeutics to Present at the H.C. Wainwright 3rd Annual Kidney Virtual Conference

Jun 24, 2024, 8:58 AM EDT - 1 year ago

Akebia Therapeutics Appoints Erik Ostrowski as Chief Financial Officer and Chief Business Officer

May 23, 2024, 8:00 AM EDT - 1 year ago

Akebia Therapeutics to Present at the Jefferies Global Healthcare Conference

TheUltimatePayoff Sep. 17 at 6:43 AM

$AKBA $3.20

0 · Reply

Quinnlucky Sep. 17 at 6:42 AM

0 · Reply

Mr_Pithy Sep. 17 at 6:37 AM

1 · Reply

Noname2022 Sep. 17 at 3:55 AM

$AKBA

0 · Reply

PharmaExpert Sep. 17 at 2:48 AM

$AKBA Major Surge is Imminent! 🔥

1 · Reply

georgeyann Sep. 17 at 2:19 AM

$AKBA strong buy!

1 · Reply

buckeye1979 Sep. 17 at 1:29 AM

$AKBA I have seen a lot of dumb posts on here, but this is definitely a contender for the “here is your sign” award. Pumpers sold and promoting the stock…explain the financial benefit in that?

3 · Reply

GOLA_K Sep. 17 at 1:23 AM

$AKBA SELL, SELL, Before CRL, AKBA and now same price, What Vasio impact?? JB, Why boards are not firing you.

1 · Reply

IVAlert Sep. 17 at 1:02 AM

0 · Reply

King_JK Sep. 17 at 12:52 AM

$AKBA What did I say earlier...? Watch the CEOs and boards of directors at TSLA and OPEN! That's what truly matters to shareholders, not just rewarding the CEO with stock all the time! $TSLA $OPEN

0 · Reply

TummytheFatCat Sep. 17 at 12:50 AM

$AKBA Yall listening to the local resident pumpers $30 EOY propaganda and they probably have already sold there shares by now

2 · Reply

Aamadeus Sep. 17 at 12:09 AM

$AKBA this price move is just a shame manage by your our dear HF. This is what i hate the most investing in small caps, there is always a fragile period where short Funds and HF just mess with the company value to expose the them yo hostile takeover by big ones. Hopefully this won’t be the case here and we get out of that pit quickly. GLTA

0 · Reply

DonnyDonowitz Sep. 16 at 11:42 PM

$AKBA lookin' at those stop losses underneath be like.....

1 · Reply

Noname2022 Sep. 16 at 11:27 PM

$AKBA

0 · Reply

Electhim Sep. 16 at 10:55 PM

$AKBA looks like heading to the 200 day Support broken 😠

0 · Reply

MrWistler Sep. 16 at 10:54 PM

$AKBA the davita akba partnership will bear big fruits imo. They'll milk this tdapa to make a shit load of cash and lower patient hospitalisations, etc, which ultimately is what its about in their industry.

0 · Reply

Noname2022 Sep. 16 at 9:58 PM

$CRMD $AKBA https://lp.constantcontactpages.com/ev/reg/z9v6sd6 If your invested in the space need to be aware and following policies…

0 · Reply

Holy_boy Sep. 16 at 9:49 PM

$AKBA Father: forgive the shorts and the weak minded, for they do not know what are doing.

8 · Reply

Brb5010 Sep. 16 at 9:24 PM

$AKBA blockbuster status! 🤔

2 · Reply

MB76 Sep. 16 at 9:05 PM

$AKBA EVERYDAY the resident FUD pumpers come out HOPING to prey on what they think is a preconceived time constraint that NONE of us have placed on the SP. Who cares how long it takes; we are in this for the long haul!!!!!! What losers!!!!!!

3 · Reply

Noname2022 Sep. 16 at 8:42 PM

$CRMD $AKBA $FMS $DVA

1 · Reply

Popeye989 Sep. 16 at 8:40 PM

$AKBA remember https://www.stocktitan.net/news/AKBA/akebia-therapeutics-and-innovative-renal-care-announce-nationwide-eu7fpjbu32ru.html

0 · Reply

Market Cap	774.22M
Revenue (ttm)	160.18M
Net Income (ttm)	-69.41M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-43.33%
Debt to Equity Ratio	1.61

Volume	3,063,500
Avg Vol	3,735,452
Day's Range	N/A - N/A
Shares Out	265.15M
Stochastic %K	6%
Beta	1.02
Analysts	Strong Sell
Price Target	$7.40